-+ 0.00%
-+ 0.00%
-+ 0.00%

Oculis To Present Late-Stage Pipeline Progress Including Breakthrough Therapy And Phase 3 Milestones At 2026 J.P. Morgan Healthcare Conference

Benzinga·01/08/2026 09:29:08
Listen to the news
  • Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. alone
  • Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) expected in Q2 2026
  • Riad Sherif, M.D., Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 1.30pm PST